Fluorescent Imaging Agent

Specification  $\sim 1500~g~mol^{-1}$ 



Research use only. Not for use in diagnostic procedures.

# IVISense™ Hypoxia CA IX 680 Fluorescent Probe

**Product Number:** NEV11070

#### **DESCRIPTION**

IVISense™ Hypoxia CA IX 680 Fluorescent Probe is a Carbonic Anhydrase IX (CAIX) targeted fluorescent in vivo imaging agent that can be used to image CAIX overexpression in tumors in response to regional tumor hypoxia.

#### **MATERIAL**

Each vial contains 24 nmol of IVISense™ Hypoxia CA IX 680 Fluorescent Probe in dry solid form. Reconstitute IVISense™ Hypoxia CA IX 680 Fluorescent Probe with 1.2 mL of 1 x PBS before injecting into animals. Each vial of packaged material provides sufficient reagent for imaging approximately 10 mice (weighing ~25 grams each) when using the recommended dose of 2 nmol (100 µL) of IVISense™ Hypoxia CA IX 680 Fluorescent Probe per mouse.

STORAGE &	HANDLING
-----------	----------


- Upon receipt, IVISense™ Hypoxia CA IX 680 Fluorescent Probe should be IMMEDIATELY STORED AT 2-8 °C AND PROTECTED FROM LIGHT.
- When stored and handled properly, IVISense™ ™ Hypoxia CA IX 680 Fluorescent Probe is stable for six months from the date of shipment in dry solid
- Before opening the vial, ensure that all of the solid material is at the bottom of the vial.

	Fluorescence'		
	<ul> <li>Excitation</li> </ul>	670 nm	
	Emission	685 nm	
	Absorbance <sup>1</sup>	670 nm	
	Purity <sup>2</sup>	>90%	
	Appearance	Blue solid	
	. Absorbance and fluorescence maxima in 1xPBS		
	2. As determined by RP-HPLC	As determined by RP-HPLC and measuring absorbance a	
	nm		

**Property** 

MW

at 670 nm.



## Once reconstituted, the solution is stable up to 14 days when stored at 2-8°C and protected from light.

### IN VIVO IMAGING & APPLICATIONS

The recommended procedure for in vivo imaging with IVISense™ Hypoxia CA IX 680 Fluorescent Probe is administration via intravenous injection and imaging 24-48 hours post injection. IVISense™ Hypoxia CA IX 680 Fluorescent Probe may also be injected intraperitoneally and imaged 24 hours post injection.

The information provided in this document is for reference purposes only and may not be all-inclusive. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume liability for the accuracy or completeness of the information contained herein. Users should exercise caution when handling materials as they may present unknown hazards. Revvity shall not be liable for any damages or losses resulting from handling or contact with the product, as Revvity cannot control actual methods, volumes, or conditions of use. Users are responsible for ensuring the product's suitability for their specific application. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS, OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF NEV11070-R Rev01